CERo Therapeutics Holdings, Inc. CERO
0.00 USD 0.00 (+28.95%)
Nov 11, 2026, 3:40 PM EST
0.0039 Day range 0.0049
0.003 52-week range 0.135
- YTD
- -92.69%
- 1 year
- -95.74%
News
globenewswire.com CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial Seventh patient of the trial at the second cohort SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an…
globenewswire.com CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing…
benzinga.com SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logisticsUpdate follows SRX’s previously announced…
globenewswire.com CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers SOUTH SAN FRANCISCO, Calif, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing…
globenewswire.com CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic…
globenewswire.com CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- CERo…
globenewswire.com CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)
globenewswire.com CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings,…
globenewswire.com CERo Therapeutics Provides Shareholder Update Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead…
globenewswire.com CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new…
globenewswire.com CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on…
globenewswire.com CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings,…
globenewswire.com CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1
globenewswire.com CERo Therapeutics Announces Trading on OTCQB Market Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an…
globenewswire.com CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new…
globenewswire.com CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket 
globenewswire.com CERo Therapeutics Announces Receipt of Nasdaq Panel Determination Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC…
globenewswire.com CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics…
globenewswire.com CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Dow Surges 150 Points; Korn Ferry Earnings Top Views - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity U.S. futures were higher on Wednesday as oil futures tumbled after Donald Trump called for an "Unconditional Surrender" by Iran late Tuesday.
benzinga.com Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket 
benzinga.com Dow Dips Around 300 Points As Israel-Iran Conflict Escalates: Investor Sentiment Declines, Fear & Greed Index Moves To 'Neutral' Zone 
benzinga.com Crude Oil Rises Sharply; Jabil Earnings Top Views 
benzinga.com US Stocks Lower; Retail Sales Decline In May 
benzinga.com US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market' U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark indices were mixed in premarket.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket 
benzinga.com Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
benzinga.com Why Domino's Pizza Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session